Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma
- 18 July 2007
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 61 (5) , 855-863
Abstract
Introduction The cytotoxic activity of the farnesyltranseferase inhibitor R115777 was evaluated in cell lines representative of mantle cell lymphoma (MCL). Methods Cell growth, proliferation, and apoptosis were analyzed in four human MCL cell lines (Granta, NCEB, REC, and UPN1) in presence of R115777, alone or in combination with vincristin, doxorubicin, bortezomib, cisplatin and cytarabine. Inhibition of farnesylation was determined by the appearance of prelamin A. The antitumor activity of R115777, administered p.o. at 100, 250 and 500mg/kg, was determined in vivo in nude mice xenografted with UPN1 cells. Results R115777 inhibited the growth of MCL cell lines in vitro with inhibitory concentrations ranging between 2 and 15nM. A fifty percent decrease of cell viability was observed at concentrations comprised between 0.08 and 17μM. Apoptosis, evaluated by annexin V and activated caspase 3 staining, was induced in all cell lines, in 40 to 71% of the cells depending on the cell lines. In addition, R115777 significantly increased the cytotoxic effect of vincristine, doxorubicin, bortezomib, cisplatin and cytarabine (p=0.001, p=0.016, p=0.006, p=0.014 and p=0.007 respectively). Exposure of MCL cell lines to R115777 during 72 hours resulted in inhibition of protein farnesylation. R115777 administered p.o. twice daily for 8 consecutive days to mice bearing established s.c. UPN1 xenograft displayed cytostatic activity at the 500 mg/kg dosage. Conclusion We have demonstrated that inhibition of farnesyltransferase by R115777 was associated with growth inhibition and apoptosis of MCL cell lines in vitro and tumor xenograft stability in vivo.Keywords
This publication has 55 references indexed in Scilit:
- Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal CompartmentsCancer Research, 2007
- Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response PathwaysJournal of Clinical Oncology, 2005
- The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2004
- Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic SyndromeJournal of Clinical Oncology, 2004
- Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosisBlood, 2004
- Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesBlood, 2003
- Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective studyLeukemia, 2002
- Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the MicrotubulesJournal of Biological Chemistry, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patientsBone Marrow Transplantation, 1998